ABT Abbott Laboratories Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
11:45
Sep 01
Sep 01
Medtronic's cardiac ablation (CAS) business grew 88% globally and 139% in the US, and its US installed base for the Affera system grew 35% sequentially, indicating strong pull-through and market share gains. — Accelerating share gains in the high-growth PFA market pressure competitors like Boston Scientific and Abbott.
MED
05:12
Sep 01
Sep 01
Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings.
Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings as a watchlist, not an explicit position.
LOW
16:45
Aug 31
Aug 31
Abbott Laboratories will begin selling a new ready-to-feed version of its Similac infant.
Abbott Laboratories will begin selling a new ready-to-feed version of its Similac infant formula on Monday, marking the first use of whole milk in sterile liquid formula in the US.
18:28
Aug 25
Aug 25
FDA clears Abbott's Libre Duo 10-day dual glucose ketone monitor, the first U.S.
FDA clears Abbott's Libre Duo 10-day dual glucose ketone monitor, the first U.S. device to continuously track ketones.
09:57
Aug 21
Aug 21
A news wire reports a broad list of price target raises, cuts.
A news wire reports a broad list of price target raises, cuts, and coverage initiations across numerous stocks from various analysts, with no personal market view expressed.
23:28
Aug 20
Aug 20
Abbott continues to face roughly 1,700 lawsuits involving claims tied to 12,700 infants.
Abbott continues to face roughly 1,700 lawsuits involving claims tied to 12,700 infants, keeping legal costs and earnings risks in focus.
23:28
Aug 20
Aug 20
Abbott agrees to pay approximately 670 million dollars to settle the Gill case and about 2,000.
Abbott agrees to pay approximately 670 million dollars to settle the Gill case and about 2,000 related preterm infant formula claims.
23:05
Aug 20
Aug 20
Abbott agrees to pay 670 million dollars to settle lawsuits alleging it concealed risks of its.
Abbott agrees to pay 670 million dollars to settle lawsuits alleging it concealed risks of its premature infant formula causing a deadly bowel disease.
20:25
Aug 20
Aug 20
Abbott announces it will pay about 670 million dollars to resolve the Gill case and 2,000.
Abbott announces it will pay about 670 million dollars to resolve the Gill case and 2,000 related preterm infant formula claims, with 1,700 lawsuits for 12,700 infants still pending.
23:51
Aug 17
Aug 17
Abbott is cheap at 20 times earnings
Cramer disagrees with concerns about Abbott's acquisition, says Abbott is good, and at only 20x earnings it is still too cheap for Abbott. He would hold the stock.
MED
23:51
Aug 17
Aug 17
The stock is cheap at current multiples.
Despite concerns over a recent acquisition, the company is performing well and the stock remains too cheap at 20 times earnings.
MED
13:00
Aug 17
Aug 17
Highlights largest single-fund new positions.
Highlights largest single-fund new positions for Q2 2026, no directional view.
MED
10:56
Aug 13
Aug 13
Wolfe Research, JPMorgan, Citizens, Citi, Jefferies, RBC, Wells Fargo, Cantor Fitzgerald.
Wolfe Research, JPMorgan, Citizens, Citi, Jefferies, RBC, Wells Fargo, Cantor Fitzgerald, Roth/MKM, UBS, BofA, and Nomura issue multiple analyst upgrades and downgrades with various price target changes across a broad set of stocks.
13:08
Aug 11
Aug 11
Abbott and Google announce a multi-year collaboration focused on glucose insights.
Abbott and Google announce a multi-year collaboration focused on glucose insights and artificial intelligence technologies.
22:35
Aug 05
Aug 05
Watch Abbott, DexCom on CGM read-through
Watch ABT and DXCM as the clearest medical-device beneficiaries of TTM's CGM component strength; research read-through only, no author-owned long.
MED
12:00
Aug 05
Aug 05
Management admits its guidance was set on flawed assumptions for Type 2 retention and is now assuming no improvement in attrition trends in the second half, suggesting the problem is partially structural. — This signals a material demand signal for CGM/diabetes ecosystem, potentially impacting companies like Abbott that view the Type 2 market as a key growth vector.
MED
20:51
Aug 03
Aug 03
Medical devices (IHI, MDT, ABT, BAX) outperforming.
Healthcare/medical devices are showing relative strength improvement as funds reduce tech weight. IHI, Medtronic, Abbott, and Baxter have started outperforming in the last month and a half and should continue.
MED
07:18
Jul 25
Jul 25
Abbott trades at 16x forward earnings, with strong June-quarter results showing wider margins and new product launches (arrhythmia treatments, diabetes monitoring, GLP-1 nutrition). The stock’s discount to the S&P 500 and 15% analyst upside target create a clear entry point as fears over utilization are overblown. Abbot offers a defensive growth story with a reasonable valuation, making it a core medtech value play. Further slowdown in healthcare utilization or Medicaid cuts could pressure sales; competition in diabetes monitoring.
HIGH
14:12
Jul 21
Jul 21
Abbott threatened by GLP-1 diabetes reduction.
Concerned about Abbott Laboratories because GLP-1 weight-loss drugs may reduce diabetes prevalence, threatening Abbott's core diabetes business, so he did not recommend the stock despite a better quarter.
MED
18:43
Jul 17
Jul 17
Abbott Laboratories raised its full-year EPS guidance on strong medical device sales and margin.
Abbott Laboratories raised its full-year EPS guidance on strong medical device sales and margin expansion, but the neutral Quant rating and declining diagnostics segment keep the outlook balanced.
18:15
Jul 16
Jul 16
Buy ABT on near-term momentum continuation; Cramer expects further upside support following.
Buy ABT on near-term momentum continuation; Cramer expects further upside support following a strong up day, though no specific fundamental catalyst is cited.
MED
16:40
Jul 16
Jul 16
Abbott Laboratories raised its 2026 profit guidance after a stronger-than-expected second.
Abbott Laboratories raised its 2026 profit guidance after a stronger-than-expected second quarter driven by improved performance across most of its business lines.
16:14
Jul 16
Jul 16
Abbott reported strong second-quarter 2026 results with accelerating sales growth.
Abbott reported strong second-quarter 2026 results with accelerating sales growth, margin expansion, and raised full-year guidance driven by momentum across diagnostics, nutrition, and medical devices.
13:53
Jul 16
Jul 16
Abbott Laboratories shares extended their gain to 14 percent.
Abbott Laboratories shares extended their gain to 14 percent, marking the largest single-day increase since 2002.
13:39
Jul 16
Jul 16
Abbott Laboratories shares surged to a session high of 11 percent.
Abbott Laboratories shares surged to a session high of 11 percent, marking their largest single-day gain since 2020.
13:18
Jul 16
Jul 16
Abbott Laboratories shares extended gains to 5.7 percent after the company raised its full-year.
Abbott Laboratories shares extended gains to 5.7 percent after the company raised its full-year guidance.
13:00
Jul 16
Jul 16
Guidance is maintained on revenue and raised on EPS, with momentum building across nutrition, EP, core lab, and cancer diagnostics; management is confident in second-half acceleration.
HIGH
12:32
Jul 16
Jul 16
US pre-market movers show mixed sector action with TSM down on capex hike despite strong.
US pre-market movers show mixed sector action with TSM down on capex hike despite strong results, UAL lower on light guidance, JBHT up on earnings beat, ATAI surging on LLY acquisition, UNH and ABT rising on strong earnings and outlook, DSGR jumping on buyout, and LULU falling on a Truist downgrade.
11:56
Jul 16
Jul 16
The author provides a comprehensive macro and market brief highlighting geopolitical escalation.
The author provides a comprehensive macro and market brief highlighting geopolitical escalation, consumer deterioration, and technical fragility from gamma expiry and buyback blackout without stating any personal positions or forward calls.
11:36
Jul 16
Jul 16
Abbott reports second quarter sales of 12.6 billion dollars beating the IBES estimate of 12.50.
Abbott reports second quarter sales of 12.6 billion dollars beating the IBES estimate of 12.50 billion dollars and maintains its full year sales growth outlook of 6.5 to 7.5 percent.
About ABT Analyst Coverage
Buzzberg tracks ABT (Abbott Laboratories) across 20 sources. 9 bullish vs 0 bearish calls from 26 analysts. Sentiment: predominantly bullish (18%). 51 total trade ideas tracked. Past 7 days: 3 watch. Latest voices: Geoff Martha, asklivermore, Bloomberg.